HI-PRIX
Grant agreement ID: nr. 101095593
Principal investigator: Oriana Ciani (CeRGAS)
Team UB/Cergas: Sarmad Ali, Vittoria Ardito, Helen Banks, Ludovico Cavallaro, Niccolò Cusumano, Nicola Maria Fiore, Simone Ghislandi, Rosanna Tarricone (CeRGAS); Mike Drummond (York); James Robinson (Berkeley)
Partners: Bocconi University (UB, Coordinator), Universitaet Hamburg (UHAM); HTA Austria - Austrian Institute for Health Technology Assessment GmbH (AIHTA); Escuela Andaluza de Salud Publica SA (EASP); Universite Libre de Bruxelles (ULB); Office of Health Economics (OHE); Fundació Clínic per a la Recerca Biomèdica (FCRB); Hospital Clinic de Barcelona (HCB); Imperial College of Science Technology and Medicine (ICL); Erasmus Universiteit Rotterdam (EUR); Universidade Nova de Lisboa (UNL); Ecole d'Economie de Paris (PSE); Vilniaus Universitetas (VU); Fundacion Publica Andaluza Progreso y Salud (AETSA); Agenzia Italiana del Farmaco (AIFA); Infarmed – Autoridade Nacional do Medicamento e Produtos da Salude IP (INF); London School of Economics and Political Science (LSE); Servei Catala de la Salut (CATSALUT).
Sponsor: European Union's Horizon Europe Research and Innovation Action “New pricing and payment models for cost-effective and affordable health innovations” (HORIZON-HLTH-2022-IND-13-03)
Duration: January 2023-December 2025
Abstract:
The variety of innovative technologies with the potential to revolutionize the delivery of health care means that the policy toolbox will need several pricing and payment models, adapted in their design and implementation according to the specific situation. Although there are examples of novel pricing and payment models, the lack of appropriate data infrastructure, legal barriers and unwillingness to adapt current systems often prevent their use. Therefore, the overall objectives of the Health Innovation Next Generation Pricing Models (HI – PRIX) project are: i) to map and formulate new pricing and payment schemes that can be used across technology classes, therapeutic areas, setting and healthcare systems/geographies together with a related set of principles that may guide successful adjustment and flexible implementation to the context of use; ii) to investigate the impact on competitiveness, innovation, equity and affordability of a pipeline of contracting modalities for health innovations; iii) to address the challenges and concerns of payers, manufacturers, healthcare professionals, and patients about different models of pricing by sustaining an effective dialogue across stakeholders’ groups about the trade-offs between affordability, innovation and patient access. The HI-PRIX Consortium involves 18 partners from 10 European countries, including academic institutions, public authorities, healthcare providers, and independent research organizations. Through theoretical models, quantitative simulation, qualitative research work and case-studies, this three-year project structured around 10 WPs, will generate new evidence on the role of public sector in R&D and indirect medical and environmental costs in pricing and reimbursement determinations, on the pricing dynamics over pharmaceutical products’ lifecycle, on the impact of policies and incentives on the competitiveness, innovativeness and equity in the healthcare system.
Editorials:
How to Expand Access to Healthcare Innovation discover more